Novartis is dedicated to research in therapeutic areas with high unmet patient needs. Join us at #ASH24 to explore our latest research in #oncology and #hematology at booth 2529.
About us
Committed to providing US health care professionals medical and scientific information about Novartis products and disease education. See our community guidelines: http://bit.ly/2JnT2CP. If you have a medical inquiry, please contact us via http://bit.ly/31YWY3F or call us at 1-844-NVSocial. Our posts are for US HCP audiences only. • Please be patient; sometimes responses take time. • Please do not include your personal information in your posts. • We will respond to your questions/comments M-F, 9a-5p EST (no holidays). • The purpose of our posts is to share disease state education and congress information. We reserve the right to hide or remove any post that mentions specific product(s) or treatment(s) as that is not the intent of our posts. • If needed, we’ll show you how to get us your contact and case info securely. • We reserve the right to engage with posts on a case-by-case basis; not all posts will be acknowledged or responded to. • Novartis Pharmaceuticals Corporation does not endorse and is not responsible for the content of third-party links we may share. • Replying to or mentioning users does not imply our endorsement.
- Website
-
https://medinfo.novartispharmaceuticals.com
External link for Novartis US Medical
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
Updates
-
Adherence is critical in patients with Multiple Sclerosis (MS), as it reduces relapse risk, decreases MS-related hospitalizations, and slows disability progression. However, there is limited persistence and adherence data on subcutaneous disease-modifying therapy (DMT) compared to other self-administered injectables and oral medications in patients with MS. Read the results of a real-world persistence and adherence study of injectable and oral DMTs in MS patients.
-
Interested in the latest results about patients living with relapsing #MultipleSclerosis (MS) who switched anti-CD20 therapies? Watch Dr Brandon Brown, Senior Medical Director at Novartis, share the latest data from a phase 3b exploratory study evaluating MRI lesions, immunoglobulin levels, and safety in patients with #MS who switched anti-CD20 therapies. These results were presented in a late-breaking abstract session in September at #ECTRIMS2024. Watch here: https://lnkd.in/ggfcCUG4 #Neurology #MSAwareness
-
-
Explore diagnosis, severity, and patient-reported outcome tools like the UAS7 in this video to help understand the impact of #ChronicSpontaneousUrticaria (CSU) on patients’ quality of life. https://lnkd.in/gSvbwzej #CSU #dermatology #allergy #DermPA #urticaria
-
Still enjoying learnings about the latest research related to Lp(a) at #AHA24? Watch and listen to clinical pharmacist Mary Katherine Cheeley's call to action for improving education about elevated Lp(a) for both HCPs and patients: "I don't think providers are aware enough about elevated Lp(a). [...] I think we're doing a better job at raising awareness." https://lnkd.in/eTwX3rAy
Learn more about Lp(a) by checking out the Halls of Science website
-
If you are in Chicago for #AHA24, stop by the Novartis Medical Booth (#1308) from November 16-18 to: ✅ Explore Lp(a)'s structure and unique mechanism of disease through a physical 3D structure, the WebAR technology and the NEWLY updated HoloLens experience ✅ Learn about elevated Lp(a) being a risk driver for #ASCVD from Medical Experts ✅ Test your knowledge by playing our Premature ASCVD Quiz ✅ Try our new interactive tool, Lp(a) Heat Map, to see how Lp(a) testing rates in your state compare to the national level https://lnkd.in/gJ_25S8h
-
If you are in Chicago for #AHA24, listen in as lipid specialist Nicole Ciffone, NP, discusses the importance of Lp(a) screening, “we need to look for what are the other drivers for the cardiovascular event that this patient’s having or that they’re at risk of having.” We hope you will be joining this important conversation at #AHA24 by visiting the Novartis Medical Booth (#1308)! https://lnkd.in/eTwX3rAy
Learn more about Lp(a) at the Novartis Medical Booth (#1308) at AHA24!
-
At ACR 2024, new secondary data will be presented from the phase 3 INVIGORATE-1 and INVIGORATE-2 trials. Join our two poster presentations at #ACR24 on post hoc analyses of the INVIOGRATE-1 and INVIGORATE-2 trials led by Dr. Atul Deodhar and Dr. Alan Kivitz. These studies evaluated potential predictors of clinical response to a biologic inhibitor of interleukin (IL)-17A in patients with #AxialSpondyloarthritis (#axSpA) or #PsoriaticArthritis (#PsA). https://lnkd.in/ekuwqk7w
-
At ACR 2024, key data will be presented on real-world treatment patterns among patients newly diagnosed with axial spondyloarthritis (axSpA). Attend our poster presentation at #ACR24 to hear Dr. Andrew Concoff discuss new data from a large US rheumatology network. This study highlights the extensive use of biologic disease-modifying rheumatologic drugs in the real-world management of #AxialSpondyloarthritis (#axSpA). https://lnkd.in/ekuwqk7w
-
-
Join us at #AHA24 on Saturday, November 16, 12:30 PM CT at the Learning Studio II for an informative presentation, Finding Lp(a): "little" Things, Big Consequences. Experts will share updates supporting Lp(a)-driven CVD and premature CVD, as well as discuss the role of laboratory and imaging modalities in improving CV risk assessment in the context of elevated Lp(a). https://lnkd.in/eTwX3rAy
Come to Our Lp(a) Learning Studio